RxDoctor Payments Data

Jeffrey Steinberg, MD

Neurology · Plantation, FLNPI 1497706212

Payments from drug & device makers

$76,059in general payments, 2019–2025

Across 527 payments — averaging $144.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$58K
  • Teva Pharmaceuticals USA, Inc.$13K
  • Lilly USA, LLC$795
  • Johnson & Johnson$514
  • Jazz Pharmaceuticals Inc.$492
  • Upsher-smith Laboratories LLC$471
  • plus $3K from 36 others

What the payments were for

  • Consulting fees$2520%
  • Speaking & faculty fees$63,87084%
  • Travel & lodging$5881%
  • Food & beverage$11,17715%
  • Education$1720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,059 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$48,333
Medicare patients
65
Services billed
2,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5044$368,179
Teriflunomide11$68,518
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen28$993
Celecoxib16$694
Topiramate21$544
Clonazepam40$329
Pregabalin16$298
Vitamin D2Ergocalciferol (Vitamin D2)46$267
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$261
Gabapentin17$215
Oxcarbazepine14$197
Carbidopa-LevodopaCarbidopa/Levodopa32$177
Alprazolam37$166
Quetiapine Fumarate12$155
Diazepam31$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$91$368,17944 claims
Upsher-smith Laboratories LLCTopiramate$471$54421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →